TEVA - Teva Pharmaceutical Industries Limited

NYSE - Nasdaq Real-time price. Currency in USD
17.25
-0.31 (-1.79%)
As of 2:18PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close17.56
Open17.53
Bid17.25 x 1400
Ask17.26 x 1400
Day's range16.97 - 17.57
52-week range10.85 - 33.82
Volume5,644,557
Avg. volume12,653,820
Market cap17.536B
Beta1.02
PE ratio (TTM)N/A
EPS (TTM)-16.26
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.29
Trade prices are not sourced from all markets
  • Teva Chairman Says Tariffs Won't Have a Major Impact on Biotech
    Bloomberg Video16 days ago

    Teva Chairman Says Tariffs Won't Have a Major Impact on Biotech

    Apr.09 -- Teva Chairman Sol Barer discusses the impact he believes potential tariffs would have on the biotech industry. He speaks with Bloomberg's Vonnie Quinn and Shery Ahn on "Bloomberg Markets."

  • Reutersyesterday

    Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc (AMGN.O), Eli Lilly and Co (LLY.N) and other makers of new migraine medicines to try and fix it. Express Scripts (ESRX.O) told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Reuters - UK Focusyesterday

    FOCUS-Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Reutersyesterday

    Express Scripts targets new migraine drugs to change U.S. pricing dynamic

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • Analysts’ Recommendations for Eli Lilly & Co. on April 20
    Market Realist2 days ago

    Analysts’ Recommendations for Eli Lilly & Co. on April 20

    Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.

  • Business Wire2 days ago

    Teva to Report First Quarter 2018 Financial Results on May 3, 2018

    Teva Pharmaceutical Industries Ltd. announced today that it will release its first quarter 2018 financial results on Thursday, May 3, 2018 at 7:00 a.m. ET.

  • Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations
    Market Realist6 days ago

    Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations

    Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.

  • Business Wire6 days ago

    Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership

    Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines. No significant (material) net financial transfer between Teva and P&G will result from the dissolution. PGT Healthcare has grown into a significant presence in over 50 countries, mainly in Europe and Asia, using market-leading brands such as Vick’s and ratiopharm.

  • Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
    Market Realist7 days ago

    Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio

    In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.

  • Jazz Pharmaceuticals: How It’s Positioned before 1Q18
    Market Realist7 days ago

    Jazz Pharmaceuticals: How It’s Positioned before 1Q18

    In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.

  • Novartis’s 1Q18 Estimates: Expectations for Sandoz
    Market Realist7 days ago

    Novartis’s 1Q18 Estimates: Expectations for Sandoz

    Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.

  • Business Wire8 days ago

    Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of Neurology

    Teva Pharmaceutical Industries Ltd. today announced 38 scientific abstracts across five difficult-to-treat disorders of the central nervous system will be presented at the 70th Annual Meeting of the American Academy of Neurology in Los Angeles from April 21-27, 2018.

  • AbbVie’s Imbruvica in 4Q17 and Fiscal 2017
    Market Realist8 days ago

    AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

    AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.

  • Reuters10 days ago

    Israeli unions warn Teva Pharm over plan to close Ashdod plant

    Israel's main labour federation intends to strike or take legal action against Teva Pharmaceutical Industries (TEVA.TA) if the drugmaker does not suspend a decision to close a plant in the port city of Ashdod, it said on Sunday. Debt-laden Teva (TEVA.N), the world's largest generic drugmaker and Israel's biggest company, said last week that it would close the unprofitable plant in March 2019 after failing to find a buyer for the facility. In a letter to Teva's management, the Histadrut federation said the company's decision was contrary to a previous declaration that it would retain most of its activities in Israel.

  • Israeli unions warn Teva Pharm over plan to close Ashdod plant
    Reuters10 days ago

    Israeli unions warn Teva Pharm over plan to close Ashdod plant

    Israel's main labor federation intends to take labor or legal action against Teva Pharmaceutical Industries (TEVA.TA) if the drugmaker does not suspend a decision to close a plant in the Israeli port city of Ashdod, it said on Sunday. Debt-laden Teva (TEVA.N), the world's largest generic drugmaker and Israel's biggest company, said last week that it would close the unprofitable plant in March 2019 after failing to find a buyer for the facility. In a letter to Teva's management, the Histadrut federation said the company's decision was contrary to a prior declaration that it would retain most of its activities in Israel.

  • 3 Top Healthcare Stocks to Buy in April
    Motley Fool12 days ago

    3 Top Healthcare Stocks to Buy in April

    April could be the perfect time to pick up shares in these top healthcare stocks.

  • Alexion to Acquire Wilson Therapeutics for $855 Million
    Market Realist12 days ago

    Alexion to Acquire Wilson Therapeutics for $855 Million

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.

  • Are Drug Prices Too Low?
    Bloomberg14 days ago

    Are Drug Prices Too Low?

    Generic makers say they may stop making medicines that don’t turn a profit.

  • Analyst Recommendations for Teva Pharmaceutical in April 2018
    Market Realist15 days ago

    Analyst Recommendations for Teva Pharmaceutical in April 2018

    In December 2017, the FDA accepted Teva Pharmaceutical Industries’ (TEVA) BLA (Biologics License Application) for fremanezumab for the preventive treatment of migraine. In February 2018, the European Medicines Agency accepted the MAA (Marketing Authorization Application) for fremanezumab for the treatment of adults with episodic and chronic migraine. In January 2018, the FDA approved Teva Pharmaceutical’s Trisenox and tretinoin combination therapy for the treatment of individuals with newly-diagnosed, low-risk APL (acute promyelocytic leukemia) with a presence of PML/RAR alpha gene expression.

  • A Look at Teva Pharmaceutical’s Specialty Medicines Segment
    Market Realist15 days ago

    A Look at Teva Pharmaceutical’s Specialty Medicines Segment

    In 4Q17, Teva Pharmaceutical Industries’ (TEVA) specialty medicines segment generated revenues of $1.8 billion compared to $2.2 billion in 4Q16. That was a 19% YoY (year-over-year) decline.

  • Teva Pharmaceutical’s Specialty Medicines Segment Performance
    Market Realist15 days ago

    Teva Pharmaceutical’s Specialty Medicines Segment Performance

    In fiscal 2017, Teva Pharmaceutical Industries’ (TEVA) CNS (central nervous system) products generated revenues of $4.4 billion compared to $5.3 billion in 2016. That’s a 16% decline on a YoY (year-over-year) basis.

  • Teva Pharmaceutical’s Generic Medicines Segment in 2017
    Market Realist16 days ago

    Teva Pharmaceutical’s Generic Medicines Segment in 2017

    In fiscal 2017, Teva Pharmaceutical Industries’ (TEVA) generic medicines segment reported revenues of $12.3 billion compared to $12 billion in 2016, which was a 2% YoY (year-over-year) growth.

  • Teva Pharmaceutical’s Performance in 4Q17 and 2017
    Market Realist16 days ago

    Teva Pharmaceutical’s Performance in 4Q17 and 2017

    In 4Q17, Teva Pharmaceutical Industries (TEVA) reported revenues of $5.5 billion compared to $6.5 billion in 4Q16. That’s a 16% growth on a YoY (year-over-year) basis and a 3% growth on a quarter-over-quarter basis.

  • Teva Pharm to close plant in Israel after no buyer found
    Reuters16 days ago

    Teva Pharm to close plant in Israel after no buyer found

    Debt-laden Teva Pharmaceutical Industries said on Monday it would close an unprofitable plant in the Israeli port city of Ashdod in March 2019 after failing to find a buyer for the facility. Teva, the world's largest generic drugmaker and Israel's biggest company, said in a statement half of the factory's 175 workers would lose their jobs in the coming months with the rest continuing to work until the plant closes. In December, Teva said it would cut 14,000 jobs - 25 percent of its global workforce - and close many plants as part of a restructuring aimed at helping to pay down debts.

  • How Did Sandoz Perform in 4Q17 and Fiscal 2017?
    Market Realist23 days ago

    How Did Sandoz Perform in 4Q17 and Fiscal 2017?

    How Is Novartis Positioned after 4Q17?

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes